Original Article

You have full text access to this OnlineOpen article

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients

  1. Alok A. Khorana MD1,†,*,
  2. Charles W. Francis MD1,
  3. Eva Culakova PhD2,
  4. Nicole M. Kuderer MD2,
  5. Gary H. Lyman MD, MPH2

Article first published online: 4 OCT 2007

DOI: 10.1002/cncr.23062

Issue

Cancer

Cancer

Volume 110, Issue 10, pages 2339–2346, 15 November 2007

Additional Information

How to Cite

Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M. and Lyman, G. H. (2007), Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, 110: 2339–2346. doi: 10.1002/cncr.23062

Author Information

  1. 1

    James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York

  2. 2

    Duke University Medical Center and the Duke Comprehensive Cancer Center, Durham, North Carolina

  1. †

    Fax: (585) 273-1042.

*James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave., Box 704, Rochester, NY 14642

Publication History

  1. Issue published online: 2 NOV 2007
  2. Article first published online: 4 OCT 2007
  3. Manuscript Accepted: 29 MAY 2007
  4. Manuscript Revised: 22 MAY 2007
  5. Manuscript Received: 3 APR 2007

Funded by

  • National Cancer Institute. Grant Number: 1K23 CA120587-01A1

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (136K)

REFERENCES

  • 1
    Khorana AA. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost. 2003; 1: 2463–2465.
    Direct Link:
  • 2
    Heit JA,Silverstein MD,Mohr DN,Petterson TM,O'Fallon WM,Melton LJ3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160: 809–815.
  • 3
    Khorana AA,Francis CW,Culakova E,Kuderer NM,Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5: 632–634.
    Direct Link:
  • 4
    Sorensen HT,Mellemkjaer L,Olsen JH,Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343: 1846–1850.
  • 5
    Chew HK,Wun T,Harvey D,Zhou H,White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166: 458–464.
  • 6
    Prandoni P,Lensing AW,Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100: 3484–3488.
  • 7
    Elting LS,Escalante CP,Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164: 1653–1661.
  • 8
    Levitan N,Dowlati A,Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78: 285–291.
  • 9
    Khorana AA,Francis CW,Culakova E,Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104: 2822–2829.
    Direct Link:
  • 10
    Khorana AA,Francis CW,Culakova E,Fisher RI,Kuderer NM,Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006; 24: 484–490.
  • 11
    Sallah S,Wan JY,Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002; 87: 575–579.
  • 12
    Stein PD,Beemath A,Meyers FA,Skaf E,Sanchez J,Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006; 119: 60–68.
  • 13
    Silverstein MD,Heit JA,Mohr DN,Petterson TM,O'Fallon WM,Melton LJ3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158: 585–593.
  • 14
    Levine MN,Gent M,Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988; 318: 404–407.
  • 15
    Saphner T,Tormey DC,Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991; 9: 286–294.
  • 16
    Cavo M,Zamagni E,Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 2002; 100: 2272–2273.
  • 17
    Kabbinavar F,Hurwitz HI,Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21: 60–65.
  • 18
    Agresti A. Categorical Data Analysis. 2nd ed. New York: Wiley-Interscience; 2002.
  • 19
    White RH,Zhou H,Murin S,Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005; 93: 298–305.
  • 20
    Patel RK,Ford E,Thumpston J,Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost. 2003; 90: 835–838.
  • 21
    McGarry LJ,Thompson D. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice. Clin Ther. 2004; 26: 419–430.
  • 22
    Blom JW,Vanderschoot JP,Oostindier MJ,Osanto S,van der Meer FJ,Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006; 4: 529–535.
    Direct Link:
  • 23
    Kalra MK,Maher MM,D'Souza R,Saini S. Multidetector computed tomography technology: current status and emerging developments. J Comput Assist Tomogr. 2004; 28( Suppl 1): S2–6.
  • 24
    Gladish GW,Choe DH,Marom EM,Sabloff BS,Broemeling LD,Munden RF. Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology. 2006; 240: 246–255.
  • 25
    Kniffin WDJr,Baron JA,Barrett J,Birkmeyer JD,Anderson FAJr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994; 154: 861–866.
  • 26
    White RH,Romano PS,Zhou H,Rodrigo J,Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158: 1525–1531.
  • 27
    Arnason T,Wells PS,van Walraven C,Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res. 2006; 118: 253–262.
  • 28
    Quan H,Parsons GA,Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care. 2002; 40: 675–685.
  • 29
    Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007; 356: 1438–1444.
  • 30
    Geerts WH,Pineo GF,Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126( 3 suppl): 338S–400S.
  • 31
    Wagman LD,Baird MF,Bennett CL, et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2006; 4: 838–869.
  • 32
    Kakkar AK,Levine M,Pinedo HM,Wolff R,Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003; 8: 381–388.
  • 33
    Kahn SR,Panju A,Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007; 119: 145–155.
View Full Article (HTML) Get PDF (136K)